Gemcitabine in locally advanced and/or metastatic bladder cancer

Critical Reviews in Oncology/Hematology

Volumn 34, Issue 3, 2000, Pages 175-183

  Von Der Maase, Hans ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Bladder cancer; Chemotherapy; Gemcitabine

Indexed keywords

CISPLATIN; DOXORUBICIN; GEMCITABINE; METHOTREXATE; PACLITAXEL; VINBLASTINE;

ADVANCED CANCER; BLADDER CANCER; CANCER SURVIVAL; CLINICAL TRIAL; HUMAN; META ANALYSIS; METASTASIS; NEUTROPENIA; REVIEW; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME;

EID: 0034030632     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(00)00060-3     Document Type: Review

References (38)

1. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999;49(1):33-64.
2. Scher HI, Shipley WU, Herr H Jr. Cancer of the bladder. In: DeVita VT Jr, Hellman S, Rosenburg SA, editors. Cancer: Principles and Practice of Oncology, vol. 1 and 2, 5th ed. Philadelphia, PA: J.B. Lippincott, 1997:1300-22.
3. American Cancer Society. Cancer Resource Center on Urinary Bladder Cancer. American Cancer Society, www.cancer.org. 1999.
4. Droller MJ. Bladder cancer: state-of-the-art care. CA Cancer J Clin 1998;48:269-84.
5. Jensen OM, Esteve J, Moller H, Renard H. Cancer in the European community and its member states. Eur J Cancer 1990;26:1167-256.
6. Roth BJ. Chemotherapy for advanced bladder cancer. Semin Oncol 1996;5:633-44.
7. Sternberg CN, Yagoda A, Scher HI, et al. M-VAC for advanced transitional cell carcinoma of the urothelium: efficacy, and patterns of response and relapse. Cancer 1989;64:2448-58.
8. Harker W, Meyers FJ, Freiha FS, et al. Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract a Northern California Oncology Group study. J Clin Oncol 1985;3:1463-70.
9. Logothetis CJ, Samuels ML, Ogden S, et al. Cyclophosphamide, doxorubicin and cisplatin chemotherapy for patients with locally advanced urothelial tumors with or without nodal metastases. J Urol 1985;134:460-4.
10. Scher HI, Bahnson R, Cohen S, et al. NCCN urothelial cancer practice guidelines. National Comprehensive Cancer Network. Oncology 1998;12:225-71.
11. Sternberg CN, Yagoda A, Scher HI, et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 1985;133:403-7.
12. Dodd PM, McCaffrey JA, Herr A, et al. Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. J Clin Oncol 1999;17:2546-52.
13. Tannock I, Gospodarowicz M, Connolly J, et al. MVAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: The Princess Margaret Hospital experience. J Urol 1989;142:289-92.
14. Igawa M, Ohkuchi T, Ueki T, et al. Usefulness and limitations for methotrexate, vinblastine, doxorubicin and cisplatin for the treatment of advanced urothelial cancer. J Urol 1990;144:662-5.
15. Connor JP, Olsson CA, Benson MC, et al. Long-term follow-up in patients treated with methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) for transitional cell carcinoma of urinary bladder: cause for concern. Urology 1989;34:353-6.
16. Boutan-Laroze A, Mahjoubi M, Droz JP, et al. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced carcinoma of the bladder. Eur J Cancer 1991;27:1690-4.
17. Sternberg CN, de Mulder P, Fossa S, et al. Interim toxicity analysis of a randomized trial in advanced urothelial tract tumors of high-dose intensity M-VAC chemotherapy (HD-M-VAC) and recombinant human granulocyte colony stimulating factor (G-CSF) versus classic M-VAC chemotherapy (EORTC 30924). Proc Am Soc Clin Oncol 1997;16:320a (abstr).
18. Loehrer P, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a Cooperative Group Study. J Clin Oncol 1992;10:1066-73.
19. Logothetis CJ, Dexeus FH, Finn L, et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 1990;8:1050-5.
20. Bajorin DF, Dodd PM, Mazumdar M, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 1999;17:3173-81.
21. Saxman SB, Propert KJ, Einhorn LH, et al. Long-term followup of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1997;15:2564-9.
22. Pollera CF, Ceribelli A, Crecco M, et al. Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study. Ann Oncol 1994;5:182-4.
23. Lorusso V, Pollera CF, Antimi M, et al. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Eur J Cancer 1998;34:1208-12.
24. Stadler WM, Kuzel T, Roth B, Raghavan D, Dorr FA. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 1997;15:3394-8.
25. Moore MJ, Tannock IF, Ernst DS, Huan S, Murray N. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 1997;15:3441-5.
26. Gebbia V, Testa A, Borsellino N, et al. Single agent 2′,2′-difluorodeoxycytidine in the treatment of metastatic urothelial carcinoma: a phase II study. Clin Ter 1999;150:11-5.
27. Peters GJ, Bergman AM, Ruiz van Haperen VW, et al. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 1995;22(suppl 11):72-9.
28. von der Maase H, Andersen L, Crino L, Weinknecht S, Dogliotti L. Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial. Ann Oncol 1999;10:1461-5.
29. Kaufman D, Stadler W, Carducci M, et al. Gemcitabine (GEM) plus cisplatin (CDDP) in metastatic transitional cell carcinoma (TCC): final results of a phase II study. Proc Am Soc Clin Oncol 1998;17(abstr 1235):320a.
30. Moore JM, Winquist EW, Murray N, et al. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1999;17:2876-81.
31. Scher HI, Norton L. Chemotherapy for urothelial tract malignancies: breaking the deadlock. Sem Surg Oncol 1992;8:316-41.
32. Bruni GC, Posca T, Celiento G. Gemcitabine and Navelbine in elderly patients with bladder cancer: a pilot study. Ann Oncol 1998;9(suppl 4):64.
33. Perez C, Nogue M, Domenech M, et al. Gemcitabine-carboplatinum in locally advanced or metastatic bladder cancer patients with renal failure. Eur J Cancer 1999;35(suppl 2):S81.
34. Marini L, Sternberg CN, Sella A, et al. A new regimen of gemcitabine and paclitaxel in previously treated patients with advanced transitional cell carcinoma. Proc Am Soc Clin Oncol 1999;18(abstr 1335):346a.
35. Meluch AA, Greco FA, Burris HA, et al. Gemcitabine and paclitaxel in combination for advanced transitional cell carcinoma (TCC) of the urothelial tract: a trial of the Minnie Pearl Research Network. Am Proc Soc Clin Oncol 1999;18(abstr 1338):347a.
36. Bellmunt J, Guillem V, Paz-Ares J. A phase II trial of paclitaxel, cisplatin and gemcitabine (TCG) in patients (pts) with advanced transitional cell carcinoma (TCC) of the urothelium. Am Proc Soc Clin Oncol 1999;18(abstr 1279):332a.
37. Vaishampayan U, Smith D, Redman, et al. Phase II evaluation of carboplatin, paclitaxel and gemcitabine in advanced urothelial carcinoma. Am Proc Soc Clin Oncol 1999;18:(abstr 1282) 333a.
38. Rothenberg ML, Sharma A, Weiss GR, et al. Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors. Ann Oncol 1998;9:733-8.